Mesenchymal stem cell treatment in a critically ill COVID-19 patient: a case report.

Autor:	Zengin R; Department of Infectious Diseases, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey., Beyaz O; Department of Internal Medicine, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey., Koc ES; Department of Internal Medicine, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey., Akinci IO; Department of Anesthesiology and Reanimation, Acibadem Mehmet Ali Aydinlar University School of Medicine, Turkey., Kocagoz S; Department of Infectious Diseases, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey., Sagcan G; Department of Pulmonary Medicine, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey., Ovali E; Department of Hematology, Acibadem Labcell Laboratories, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey., Cuhadaroglu C; Department of Pulmonary Medicine, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey.
Jazyk:	angličtina
Zdroj:	Stem cell investigation [Stem Cell Investig] 2020 Sep 08; Vol. 7, pp. 17. Date of Electronic Publication: 2020 Sep 08 (Print Publication: 2020).
DOI:	10.21037/sci-2020-024
Abstrakt:	An outbreak of a new coronavirus causing severe respiratory disease (COVID-19) was first reported in China and rapidly spread worldwide. Clinical spectrum changes from asymptomatic infection to severe illness and even death, and no specific treatment is currently available. A range of antiviral, antimalarial and antibiotic agents are being used. We report a case of a COVID-19 patient that progressed to severe disease requiring intubation and intensive care. We performed mesenchymal stem cell (MSC) transplantation considering the signs showing persistent excessive immune response and deterioration despite all supportive and drug therapies. The two rounds of transplantation did not result in any severe complications and was well-tolerated. Clinical signs were improved. The use of MSC therapy may be considered for compassionate use in selected patients. Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/sci-2020-024). The authors have no conflicts of interest to declare. (2020 Stem Cell Investigation. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu